Oct 22 (Reuters) - Boston Scientific ( BSX ) raised its

annual profit forecast on Wednesday, after the medical device

maker beat third-quarter profit estimates on strong demand for

its heart devices.

The company, which generates most of its revenue from heart

devices such as pacemakers and stents, has benefited from rising

demand for surgical procedures, helping offset broader concerns

over healthcare spending.

Larger rival Johnson & Johnson ( JNJ ) last week also

reported a 6.8% rise in quarterly medical devices sales.

Boston Scientific ( BSX ), last week, said it will buy the remaining

equity in privately held Nalu Medical for about $533 million in

cash, expanding its portfolio of treatments for chronic pain.

Boston Scientific ( BSX ), which also makes equipment for

gastrointestinal and pulmonary treatments, expects 2025 adjusted

profit per share to be between $3.02 and $3.04, compared to its

prior range of $2.95 to $2.99.

It said last quarter that the company anticipates a

full-year tariff headwind of about $100 million, down from $200

million it expected earlier.

The company expects fourth-quarter adjusted profit per share

to be between 77 cents and 79 cents compared to analysts'

estimate of 76 cents per share, according to data compiled by

LSEG.

The Massachusetts-based company posted third-quarter

adjusted profit of 75 cents per share, above estimates of 71

cents per share.

Its quarterly revenue came in at $5.07 billion, topping

expectations of $4.97 billion.

The company's cardiovascular unit posted quarterly sales of

$3.34 billion, beating estimates of $3.27 billion.